Back to Directory Coleen Cunningham Email CKCunnin@UCI.edu Phone 714-456-8470 Institution University of California, Irving Address University of California, Irvine 3800 W. Chapman Ave Suite 2200 Orange, CA 92868 USA Request an Update Affiliated Studies IMPAACT 2048/HVTN 145: Phase I Study of the Safety and Pharmacokinetics of VRC07-523LS, ePGT121v1-LS, and PDGM1400LS Alone and in Combination in Breastfeeding Infants. DAIDS Number TBA Research Area Treatment Study Status In Development IMPAACT 2038: Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of Recombinant, Live-Attenuated, Bovine/Human, Parainfluenza Virus Type 3 (B/HPIV3) Vector Vaccines B/HPIV3/RSV/PreF, B/HPIV3/RSV/PreF/TM, or Placebo, Delivered via Nasal Sprayer to HPIV3-Seronegative Children 6 to 24 Months of Age DAIDS Number 39100 Research Area Cure and Immunotherapy Study Status Withdrawn IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Therapeutics Study Status Enrolling P1112: Monoclonal Antibody PK Study DAIDS Number 11903 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed P1114: Safety and Immunogenicity of an RSV Vaccine cps2 DAIDS Number 11948 Research Area Complications & Comorbidities Study Status Concluded Show All
IMPAACT 2048/HVTN 145: Phase I Study of the Safety and Pharmacokinetics of VRC07-523LS, ePGT121v1-LS, and PDGM1400LS Alone and in Combination in Breastfeeding Infants. DAIDS Number TBA Research Area Treatment Study Status In Development
IMPAACT 2038: Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of Recombinant, Live-Attenuated, Bovine/Human, Parainfluenza Virus Type 3 (B/HPIV3) Vector Vaccines B/HPIV3/RSV/PreF, B/HPIV3/RSV/PreF/TM, or Placebo, Delivered via Nasal Sprayer to HPIV3-Seronegative Children 6 to 24 Months of Age DAIDS Number 39100 Research Area Cure and Immunotherapy Study Status Withdrawn
IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Therapeutics Study Status Enrolling
P1112: Monoclonal Antibody PK Study DAIDS Number 11903 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
P1114: Safety and Immunogenicity of an RSV Vaccine cps2 DAIDS Number 11948 Research Area Complications & Comorbidities Study Status Concluded